Complete resolution of clinical signs and symptoms were comparable in the delafloxacin and vancomycin/aztreonam groups at the end of treatment, at follow-up, and a late follow-up.
Sweta GuptaContributing Writer https://www.dermatologyadvisor.com
Sweta Gupta is a freelance writer and editor with more than 10 years of experience in media and publishing. She started her career at Wiley, editing textbooks on psychology, counseling, and social work. Afterward, she transitioned to working on professional content with Medscape Education, the largest US provider of continuing medical education programs. Most recently, she managed two websites for a clinician audience: Infectious Disease Advisor and Endocrinology Advisor. She is a graduate of Rutgers University and holds a BA in English literature and a minor in psychology.